In summary, our result demonstrated that BAFF is a novel promising biomarker for differentiating IBD from IBS, and it is also a sensitive surrogate used for assessing endoscopic inflammation in IBD. This evidence concerns the gene TNFSF13B and irritable bowel syndrome.